| Chronic Hepatitis C virus (HCV) infection affects estimated 170 million individuals world-wide, including 3.9 million in USA and 30 million in China.
FusoGen by taking advantages of its advanced technology and using its experiences in the development of patented therapeutics, has completed the computer-assisted design of an HCV inhibitor, FusoPin. |
